ZLAB Zai Lab Ltd. Sponsored ADR

Zai Lab Announces Participation in November Investor Conferences

Zai Lab Announces Participation in November Investor Conferences

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will participate in the following investor conferences in November:

Goldman Sachs Asia Pacific Healthcare Forum 2022

Panel discussion: Tuesday, November 15, 2022 at 9:30 a.m. HKT

Morgan Stanley 21st Annual Asia Pacific Summit

Meetings: Wednesday, November 16, 2022

Location: Singapore

Jefferies London Healthcare Conference

Fireside Chat: Thursday, November 17, 2022 at 1:30 p.m. GMT

2022 BioCentury-BayHelix East-West Summit

Panel discussions: Several sessions available beginning on November 5, 2022 through December 30, 2022

Webcast link of Jefferies London Healthcare Conference will be available under “Events & Presentations” in the “Investor Relations” section of Zai Lab’s website. An archived replay will be available for 90 days following the event.

About Zai Lab

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders to patients in China and around the world. Our goal is to leverage our competencies and resources to positively impact human health worldwide.

For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit or follow us at .

For more information, please contact:

Investor Relations: Lina Zhang

43

Media: Christine Drury / Xiaoyu Chen

+1 (317) 385-9227 / 11

 /  

Zai Lab Limited

Source: Zai Lab Limited



EN
31/10/2022

Underlying

ZLABZai Lab Ltd. Sponsored ADR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zai Lab Ltd. Sponsored ADR

Free Trial
ZLAB Zai Lab Ltd. Sp...

Zai Lab Limited: 2 directors

Two Directors at Zai Lab Limited sold after exercising options/sold 123,799 shares at between 29.533USD and 30.047USD. The significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all th...

ZLAB ZAI LAB LTD. SPONSORED ADR
05/14/25 May 14, 2025 1 EN
 PRESS RELEASE
Free
ZLAB Zai Lab Ltd. Sp...

Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corp...

Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates Total product revenue of $69.2 million for the third quarter of 2023, representing 22% y-o-y growth; 27% y-o-y growth at constant exchange rate (CER)VYVGART® (efgartigimod alfa injection) achieved $4.9 million sales since its commercial launch in September in ChinaStrong balance sheet with a cash position of $822.2 million as of September 30, 2023, compared to $876.4 million as of June 30, 2023Company to host conference call and webcast on November 8, 2023, at 8:00 a.m. ET SHANGHAI, China and CAMBRIDGE, Mas...

November 7, 2023 1 EN
 PRESS RELEASE
Free
ZLAB Zai Lab Ltd. Sp...

Zai Lab Announces Participation in November Investor Conferences

Zai Lab Announces Participation in November Investor Conferences SHANGHAI, China and CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November 2023: Jefferies London Healthcare ConferenceFireside Chat: Wednesday, November 15th at 1:00 p.m. GMTLocation: London 6th Annual Evercore ISI HealthCONx ConferenceFireside Chat: Wednesday, November 29th at 1:45 p.m. ESTLocation: Miami A live webcast of the presentations will b...

October 26, 2023 1 EN
 PRESS RELEASE
Free
ZLAB Zai Lab Ltd. Sp...

Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Co...

Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023 - Company to Host Conference Call and Webcast on November 8, 2023, at 8:00 a.m. ET SHANGHAI, China and CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the third quarter of 2023 and recent corporate updates, after the closing of the U.S. equity markets on November 7, 2023. The Company will host a live conference call and webcast on November 8, 2023, at 8:00 a.m. ET. Conference Ca...

October 18, 2023 1 EN
 PRESS RELEASE
Free
ZLAB Zai Lab Ltd. Sp...

Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa...

Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China SHANGHAI, China and CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation for efgartigimod alfa injection (subcutaneous injection) (efgartigimod SC) for the treatment of patients with chronic inflammatory demyelinatin...

September 18, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch